Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The Clinic for Oncology and Hematology at Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH in Regensburg is active in hematologic cancer research, with studies focused on diseases such as acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and several forms of lymphoma. These trials are mainly designed to improve treatment effectiveness, deepen remission, and refine long-term disease control.
- Research in acute leukemia includes new treatment combinations for acute myeloid leukemia and acute lymphoblastic leukemia.
- Studies in chronic leukemias and lymphoid cancers examine better ways to manage CLL, SLL, mantle cell lymphoma, and follicular lymphoma.
- Myeloma trials evaluate approaches intended to strengthen response depth and sustain disease control in multiple myeloma.
Overall, this site contributes to advancing blood cancer care by testing therapies that may improve survival, response quality, and treatment tolerability.
Neoplasms
Another major focus at the Regensburg site is solid tumor research, especially cancers of the stomach, gastroesophageal junction, colon, rectum, esophagus, lung, and ovary. The studies aim to test new treatment strategies, improve survival, and support better outcomes before and after surgery.
- Gastroesophageal and gastric cancers are being studied through trials of combined systemic and perioperative treatment approaches.
- Colorectal and rectal cancer studies explore ways to improve disease-free survival and preserve organ function.
- Lung cancer, pleural mesothelioma, and other advanced solid tumors are included in trials evaluating newer immunotherapy-based strategies.
These studies reflect a broad effort to improve both curative and advanced cancer care through more effective and personalized treatment options.
Digestive System Diseases
The site also conducts research in digestive system diseases, with a strong emphasis on cancers and inflammatory conditions affecting the colon, rectum, stomach, and esophagus, as well as ulcerative colitis. The main purpose is to evaluate better therapies, improve recovery after treatment, and support more precise care decisions.
- Colorectal cancer trials examine preoperative, postoperative, and organ-preserving treatment strategies.
- Upper gastrointestinal cancer studies assess approaches for gastric and esophagogastric adenocarcinoma.
- Inflammatory bowel disease research includes work in ulcerative colitis to improve symptom control and remission.
These efforts show a clear interest in both cancer care and chronic digestive disease management.
Respiratory Tract Diseases
Within respiratory tract disease research, the site is involved in studies of non-small cell lung cancer, pleural mesothelioma, and interstitial lung disease linked to autoimmune conditions. The trials are designed to test improved treatments, measure disease control, and better understand outcomes in difficult-to-treat lung-related illnesses.
- Stage III unresectable NSCLC studies evaluate new combinations intended to delay progression.
- Pleural mesothelioma trials focus on extending survival and improving response in advanced disease.
- Interstitial lung disease research looks at reducing lung involvement and improving respiratory health.
This area highlights the center’s involvement in both thoracic oncology and non-malignant lung disease research.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
In addition to cancer-focused work, the Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH participates in research on congenital and neonatal conditions, including fetal heart development disorders. These studies aim to improve early diagnosis and support better outcomes for unborn babies with structural abnormalities.
- Fetal cardiac development research addresses underdeveloped structures on the left side of the heart.
- Trial objectives center on improving prenatal care and evaluating whether treatment during pregnancy can support growth and development.
- This work adds a maternal-fetal medicine dimension to the site’s broader clinical research portfolio.
Although smaller in scope, this area shows the site’s interest in conditions that begin before birth and may benefit from earlier intervention.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 98 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 96 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH
lock Showing 1 of 50 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 98 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 12 | Unknown | 2016-11-07 | 2026-06-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.